Ocular Therapeutics Announces 80% Rescue-Free Rate In U.S. Wet AMD Study, Promising Diabetic Retinopathy Results, And FDA Special Protocol Assessment For SOL-one Study; Highlights Significant Market Potential And Strong Team Of Retina Experts
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutics announced an 80% rescue-free rate in its U.S. Wet AMD study, promising results for diabetic retinopathy, and received an FDA Special Protocol Assessment for its SOL-one study. The company highlighted significant market potential and a strong team of retina experts during its Investor Day.
June 13, 2024 | 7:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ocular Therapeutics announced positive results in its U.S. Wet AMD study and diabetic retinopathy, along with an FDA Special Protocol Assessment for its SOL-one study. The company emphasized significant market potential and a strong team of retina experts.
The positive clinical results and FDA Special Protocol Assessment are likely to boost investor confidence and indicate strong future revenue potential. The emphasis on market potential and expert team further supports a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100